Search results
LEO Pharma reports positive data from Phase III plaque psoriasis trial
Clinical Trials Arena via Yahoo Finance· 6 days agoA total of 604 patients across 39 sites in China participated in the study. The primary goal of the...
Bryhali dosage: Form, strength, how to use, and more
Medical News Today· 4 days agoBryhali (halobetasol) is a brand-name drug prescribed to treat plaque psoriasis in adults. Bryhali belongs to a drug class called corticosteroids. Note:...
IPC Develops Consensus on Generalized Pustular Psoriasis
Medscape· 6 days agoThe IPC's definition and diagnostic criteria for GPP minimized the complexity of clinical...
Stelara interactions: Other medications, alcohol, and more
Medical News Today· 4 days agoStelara (ustekinumab) is a brand-name injectable drug prescribed for certain autoimmune conditions....
VYNE Therapeutics receives FDA approval for trial of VYN202
Clinical Trials Arena via Yahoo Finance· 7 days agoThe company expects to report top-line results from the SAD/MAD...optimal oral bioavailability. VYNE...
Celltrion USA's adalimumab-aaty biosimilar to HUMIRA® now available at low wholesale acquisition...
Rome Sentinel· 4 days agoAdalimumab-aaty is also available from Celltrion USA under the brand name YUFLYMA®, which launched in July 2023 and is available at a 5% discount to the current WAC list price of HUMIRA. Adalimumab-aaty ...
Biotech Breakthroughs: 7 Stocks Driving the Next Wave in Healthcare
InvestorPlace via Yahoo Finance· 7 days agoAmid a challenging market environment, one of your best bets could be to target biotech stocks to...
Protagonist Reports First Quarter 2024 Financial Results and Provides Corporate Update
Morningstar· 6 days agoEntered into a worldwide license and collaboration agreement for rusfertide with Takeda; Cash runway extended through Q4 2027[1]Enrollment in both Phase 3 ICONIC LEAD and ICONIC TOTAL trials ...
5 Best Undervalued Stocks To Buy In May 2024
Forbes· 5 days agoResearching undervalued stocks? We examined stocks to identify the top undervalued stocks in May 2024. Dive into the results here.
AbbVie Inc. (NYSE:ABBV) Receives $174.31 Average Target Price from Brokerages
ETF DAILY NEWS· 2 days agoShares of AbbVie Inc. (NYSE:ABBV – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the thirteen research firms that are presently covering the stock, MarketBeat ...